An experimental drug currently being trialled for influenza and Ebola viruses could have a new target: norovirus, often known as the winter vomiting virus. A team of researchers at the University of Cambridge has shown that the drug, favipiravir, is effective at reducing – and in some cases eliminating – norovirus infection in mice.
Today, we commence a month-long focus on research on stem cells. To begin, Professors Austin Smith and Robin Franklin discuss how Cambridge scientists are helping to provide a stream of new knowledge about how our bodies are made and maintained, and how stem cells can fulfil the promise of being one of medical research’s great hopes.
Launched today (26 September), Cancer Core Europe brings together six cancer centres – including the Cambridge Cancer Centre at the University of Cambridge – to link cancer research through to cancer care.
Vaccines against Salmonella that use a live, but weakened, form of the bacteria are more effective than those that use only dead fragments because of the particular way in which they stimulate the immune system, according to research from the University of Cambridge published today.
A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.